Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORKA Oruka Therapeutics	$15.00 -2.2%	$13.29	$5.49 ▼ $52.32	$574.12M	-0.35	152,245 shs	123,704 shs
PLX Protalix BioTherapeutics	$1.52 -5.6%	$1.49	$0.89 ▼ $3.10	$121.00M	-0.21	847,167 shs	933,668 shs
RZLT Rezolute	$6.46 -0.2%	$5.14	$2.21 ▼ $6.64	$562.86M	0.18	892,068 shs	446,858 shs
SLDB Solid Biosciences	$6.17 -7.6%	$5.59	$2.41 ▼ $10.37	$520.16M	2.44	1.54 million shs	1.33 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORKA Oruka Therapeutics	-2.15%	+9.73%	+5.26%	+49.11%	+1,499,999,900.00%
PLX Protalix BioTherapeutics	-5.59%	+0.66%	+10.14%	-8.98%	+63.44%
RZLT Rezolute	-0.15%	+15.98%	+26.42%	+80.95%	+48.51%
SLDB Solid Biosciences	-7.63%	-0.32%	+14.47%	+122.74%	-26.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ORKA Oruka Therapeutics	2.964 of 5 stars	3.6	0.0	3.1	2.5	0.6
PLX Protalix BioTherapeutics	3.392 of 5 stars	3.5	2.0	3.3	1.7	1.9
RZLT Rezolute	3.1909 of 5 stars	3.6	3.0	2.6	4.2	0.0
SLDB Solid Biosciences	3.5131 of 5 stars	4.6	2.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ORKA Oruka Therapeutics	3.20	Buy	$40.38	169.17% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	886.84% Upside
RZLT Rezolute	3.17	Buy	$12.20	88.85% Upside
SLDB Solid Biosciences	3.17	Buy	$15.00	143.11% Upside

Current Analyst Ratings Breakdown

Latest PLX, RZLT, ORKA, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/14/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $13.00
8/13/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $14.00
8/12/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
7/23/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
7/21/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.10 per share	N/A
PLX Protalix BioTherapeutics	$59.76M	2.02	$0.09 per share	17.80	$0.47 per share	3.23
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A
SLDB Solid Biosciences	$8.09M	59.39	N/A	N/A	$3.32 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ORKA Oruka Therapeutics	-$83.72M	-$2.81	N/A	N/A	N/A	N/A	-26.26%	-24.16%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.90	N/A	-21.03%	-30.89%	-11.74%	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-69.70%	-56.74%	N/A

Latest PLX, RZLT, ORKA, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
8/11/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.48	-$0.46	+$0.02	-$0.46	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ORKA Oruka Therapeutics	N/A	27.42	30.03
PLX Protalix BioTherapeutics	N/A	1.98	1.27
RZLT Rezolute	N/A	8.43	8.43
SLDB Solid Biosciences	N/A	9.34	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ORKA Oruka Therapeutics	56.44%
PLX Protalix BioTherapeutics	16.53%
RZLT Rezolute	82.97%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ORKA Oruka Therapeutics	24.69%
PLX Protalix BioTherapeutics	6.50%
RZLT Rezolute	18.39%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ORKA Oruka Therapeutics	N/A	37.45 million	28.20 million	N/A
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
RZLT Rezolute	40	87.00 million	71.00 million	Optionable
SLDB Solid Biosciences	100	77.87 million	76.04 million	Optionable

PLX, RZLT, ORKA, and SLDB Headlines

Recent News About These Companies

40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco Ltd

1 hour ago | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Trading 9.9% Higher on Strong Earnings

2 hours ago | americanbankingnews.com

Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.09 EPS

August 14 at 6:29 PM | marketbeat.com

Solid Biosciences Inc.: Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13 at 7:59 AM | finanznachrichten.de

Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.10 Consensus Price Target from Analysts

August 13 at 2:15 AM | americanbankingnews.com

Solid Biosciences reports Q2 EPS (42c), consensus (49c)

August 12 at 9:57 PM | msn.com

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12 at 4:07 PM | globenewswire.com

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside (SLDB)

...

August 12 at 3:33 PM | marketbeat.com

Knott David M Jr Invests $488,000 in Solid Biosciences Inc. (NASDAQ:SLDB)

August 12 at 8:17 AM | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of "Buy" from Analysts

August 11, 2025 | marketbeat.com

Solid Biosciences (SLDB) to Release Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Solid Biosciences (SLDB) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.4% - What's Next?

August 5, 2025 | marketbeat.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Solid Bio Green on Fast Track Nod

July 23, 2025 | baystreet.ca

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

July 23, 2025 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Trading 13.3% Higher - Should You Buy?

July 19, 2025 | marketbeat.com

What is HC Wainwright's Estimate for SLDB FY2027 Earnings?

July 16, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts

July 16, 2025 | marketbeat.com

SLDB - Solid Biosciences Inc Executives - Morningstar

July 15, 2025 | morningstar.comM

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, RZLT, ORKA, and SLDB Company Descriptions

Oruka Therapeutics NASDAQ:ORKA

$15.00 -0.33 (-2.15%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$14.96 -0.04 (-0.23%)

As of 08/14/2025 04:20 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Protalix BioTherapeutics NYSE:PLX

$1.52 -0.09 (-5.59%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.03 (+2.30%)

As of 04:01 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Rezolute NASDAQ:RZLT

$6.46 -0.01 (-0.15%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.52 +0.06 (+0.93%)

As of 08/14/2025 07:14 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Solid Biosciences NASDAQ:SLDB

$6.17 -0.51 (-7.63%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.16 0.00 (-0.08%)

As of 08/14/2025 07:09 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time